Catalent celebrates opening of second Shanghai facility
12th April 2019
Catalent Pharma Solutions, a global leader in clinical supply services, has announced the completion of its new, 30,000-square-foot clinical supply facility in Shanghai, China. The event was marked with an official opening ceremony at the site on April 10.
The facility, located outside of the free trade zone (FTZ) in Tangzhen, is near to both Catalent’s existing Waigaoqiao FTZ site and China’s Zhangjiang Pharma Valley area. Together, Catalent’s two Shanghai locations will provide sponsors with an optimized supply solution for studies being undertaken in China, the Asia-Pacific region and globally. It is expected to employ up to 100 people and offers comprehensive clinical supply services including FastChain demand-led supply, secondary packaging, clinical storage and local distribution, as well as clinical returns and destruction services.
At the ribbon-cutting ceremony to officially open the site, Catalent executives welcomed local government officials and local and international pharma customers. Guests were accompanied on a site tour, and the opening ceremony also featured a traditional Chinese lion dance and a symbolic light display to reflect the bright future of the site’s foundations.
“We are delighted to have already engaged customers for services in Tangzhen,” commented Roel de Nobel, Vice President, Global Operations, Catalent Clinical Supply Services. He added, “Having facilities both inside and outside the FTZ in China affords customers flexibility, convenience and streamlined logistics in support of the growing number of trials being conducted in the region.”
The Tangzhen opening follows recent investments in Singapore and Japan, strengthening Catalent’s capabilities to support clinical trials in Asia and beyond.
With sites in the U.S., U.K., Germany, Singapore, Japan and China, and an extended network of over 50 depots, Catalent’s clinical supply services can handle a broad range of international compliance and distribution requirements to support global clinical trials.